“

The risk enhancers may increase a patient's short-term, 10-year risk, or in some cases, their lifetime risk of having a cardiovascular event, then those guidelines recommend that clinicians should err on the side of early treatment, something not considered in The Task Force The Task Force, but I do want to emphasize, even if clinicians were to take the more conservative The Task Force recommendations and follow them very, very aggressively, we definitely will see a population-level impact because of the statin therapy. The Task Force's really been studied for a very, very long time and now we know The Task Force works.